EGFR and lung carcinoma: To probe the regulation of TF by mTOR in EGFR-mut tumors, we chose three EGFR-mut lung cancer lines (HCC827, H1975, and PC9) and one GBM line harboring EGFRvIII and PTEN-loss (U87MG) as disease models for treatment with structurally distinct mTORC1/2 inhibitors (mTOR inhibitors) including Rapamycin, AZD8055, WYE-125132 (WYE-132), and MTI-31 (24, 27, 28).